NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









SpyBiotech

SpyBiotech

Private
OxfordHealthcare & Life Scienceshttps://spybiotech.com/

Last Round

Grant

Mar 20, 2023

Est. Valuation

$9.73M

Total Funding Raised

$71.5M

Company Overview

SpyBiotech is a biotechnology company that develops vaccines against infectious diseases and cancer using its proprietary protein superglue technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

SpyTag/SpyCatcherprotein supergluevaccine platformVLPvirus-like particlesprotein-coupling technologybiotech platforminfectious disease vaccineoncology vaccinevaccine deliveryclinical-stage biotechbiotech licensingprotein engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SpyBiotech Comparables

Compare SpyBiotech with similar companies based on industry and business-model similarity.

SpyBiotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
nCage Therapeutics
79%
Mevox
76%
AstraZeneca
71%

SpyBiotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 20, 2023
GrantNov 1, 2022
Series AFeb 10, 2021
Convertible DebtSep 1, 2020
SeedMar 31, 2017

Key People

Founding team and executive leadership

Mark Leuchtenberger

Chief Executive Officer

Executive Team

Keith Dewedoff

Chief Financial Officer

Executive Team

SpyBiotech Investors

Notable investors and investment history

SpyBiotech investors
InvestorRounds
Braavos Investment AdvisersSeries A
GVSeed, Series A
Oxford Science EnterprisesConvertible Debt, Series A, Seed
Gates FoundationGrant
The Bill & Melinda Gates Foundation TrustGrant
Oxford Investment ConsultantsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 29, 2025

    Stuart Chaffee joins as an independent member of the Board of Directors.

  • Feb 10, 2021

    $33M round led by Braavos Investment Advisers.

SpyBiotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SpyBiotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SpyBiotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range20
Year Founded2017
Last FundingMar 20, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.